<DOC>
	<DOCNO>NCT02370888</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose , dose limit side effect , safety increase dos lenalidomide patient AML MDS small amount detectable disease allogeneic stem cell transplant .</brief_summary>
	<brief_title>Lenalidomide After Allo-Hematopoietic Cell Transplant ( HCT ) Acute Myelogenous Leukemia ( AML ) Myelodysplastic Syndromes ( MDS ) Subjects With Minimal Residual Disease</brief_title>
	<detailed_description>All subject enter screen phase receive unique subject number . This number use identify subject throughout study . Additional test include : physical examination , blood test , applicable pregnancy test perform part participation research study . Lenalidomide administer total 42 day . The start dose 2.5 mg give orally every day day 1-21 28-day cycle 2 cycle . Dose escalation de-escalation make maximum tolerated dose reach . The dose level lenalidomide follow : Dose Level 1 : 2.5 mg Dose Level 2 : 2.5 mg Dose Level 3 : 5 mg Dose Level 4 : 7.5 mg Doses take approximately time day . Subjects must instruct swallow lenalidomide capsule whole water time day . Do break , chew open capsule . Each subject keep accurate record lenalidomide dose Subject Dosing Diary . This diary keep research record source documentation lenalidomide dose . Study personnel review dose instruction subject study visit . Subjects ask bring unused drug empty drug container study site next visit reconciliation Subject Dosing Diary .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Neoplasm , Residual</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Subjects must least 18 year age Subjects must least 60 day postallogeneic transplant donor source ; Subjects must either : High risk CD34+ ( positive ) AML ( de novo secondary , WHO 2008 classification exclude acute promyelocytic leukemia ) . High risk AML define ( ) disease status beyond complete remission ( CR ) # 1 transplant ( b ) treatment relate AML ( c ) presence adverse cytogenetics include inv ( 3 ) ; ( 3 ; 3 ) ; ( 6 ; 9 ) ; ( v ; 11 ) ; 5 del ( 5q ) ; 7 ; abnl ( 17p ) complex karyotype High risk CD34+ ( positive ) MDS ( WHO 2008 classification ) . High risk define ( ) blast count ≥5 % time transplant ( b ) treatment relate MD ( c ) presence adverse cytogenetics include 7/del7q complex karyotype Achievement hematologic CR day +60 post alloHCT Subject Karnofsky performance status must ≥ 70 Neutrophil count ≥ 1.0 thou/mm3 platelet count ≥ 50 thou/mm3 Subjects must total bilirubin ≤ 2 mg/dL Subjects must serum AST ALT level ≤ 2.5 time upper limit normal Subjects must serum creatinine &lt; 2.5 time upper limit normal calculated creatinine clearance &gt; 30 ml/min CockcroftGault formula Subjects must register mandatory Revlimid REMS® program willing able comply requirement REMS® program Females childbearing potential ( i.e. , woman premenopausal surgically sterile ) may participate , provide meet following condition : Females reproductive potential must adhere scheduled pregnancy test require Revlimid REMS® program ; Written , voluntary inform consent , willingness , ability comply study procedure . CD34 ( negative ) AML MDS Inability give inform consent Absence CR day +60 alloHCT Uncontrolled active infection ( ) require intravenous antibiotic Known suspected hypersensitivity lenalidomide Grade IIIV acute GVHD extensive GVHD Not able swallow lenalidomide capsule whole Female subject pregnant nursing .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Lenalidomide</keyword>
	<keyword>Hematopoietic Stem Cell Transplantation</keyword>
	<keyword>Peripheral Blood Stem Cell Transplantation</keyword>
</DOC>